Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies

Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Xia, Maruyama, Junki, Zhou, Heyue, Fu, Yanwen, Kerwin, Lisa, Powers, Colin, Sattler, Rachel A., Manning, John T., Singh, Alok, Lim, Reyna, Healy, Laura D., Johnson, Sachi, Paz Cabral, Elizabeth, Li, Donghui, Lu, Lucy, Ledesma, Arthur, Lee, Daniel, Richards, Susan, Rivero-Nava, Laura, Li, Yan, Shen, Weiqun, Stegman, Karen, Blair, Benjamin, Urata, Shinji, Kishimoto-Urata, Magumi, Ko, Jamie, Du, Na, Morais, Kyndal, Lawrence, Kate, Rivera, Ianne, Pai, Chin-I., Bresson, Damien, Brunswick, Mark, Zhang, Yanliang, Ji, Henry, Paessler, Slobodan, Allen, Robert D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476467/
https://www.ncbi.nlm.nih.gov/pubmed/36109550
http://dx.doi.org/10.1038/s41598-022-19780-7
Descripción
Sumario:Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha and Beta variants. STI-2020 and STI-5041 were protective when administered intravenously or intranasally in the golden (Syrian) hamster model of COVID-19 challenged with the WA-1 strain or Beta variant. The ability to administer nAbs intravenously and intranasally may have important therapeutic implications and Phase 1 healthy subjects clinical trials are ongoing.

Ejemplares similares